Pentwater reports 0% stake in Centessa Pharma
Pentwater Capital Management LP and Matthew Halbower report that they no longer beneficially own any ordinary shares of Centessa Pharmaceuticals plc, represented by ADSs with CUSIP 152309100.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pentwater Capital Management LP and Matthew Halbower report that they no longer beneficially own any ordinary shares of Centessa Pharmaceuticals plc, represented by ADSs with CUSIP 152309100. Their reported beneficial ownership is 0 shares and 0% of the class, with no sole or shared voting or dispositive power. The filing confirms they now fall under the category of ownership of 5 percent or less of this class of Centessa securities.
Key Figures
Key Terms
beneficially owned financial
investment adviser financial
Ownership of 5 percent or less of a class financial
dispositive power financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Schedule 13G/A filing disclose about CNTA ownership by Pentwater Capital Management?
What is Matthew Halbower’s reported ownership in Centessa Pharmaceuticals (CNTA)?
Why is Pentwater listed as owning 5 percent or less of CNTA stock?
Which securities of Centessa Pharmaceuticals (CNTA) are covered in this Schedule 13G/A?
Who are the reporting persons in this CNTA Schedule 13G/A amendment?
AI-generated analysis. How Rhea-AI works. Not financial advice.